News
QURE
6.71
-0.59%
-0.04
Buy Rating Affirmed for uniQure: Promising Gene Therapy Pipeline and Solid Financial Outlook
TipRanks · 1h ago
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), uniQure (QURE)
TipRanks · 3h ago
Recap: uniQure Q4 Earnings
UniQure reports its Q4 earnings results on February 28. The company missed estimates by 6.0% and missed revenue by $96.06 million. UniQure is expected to report earnings of $-1.53 per share. Last quarter the company missed on EPS by $1.03.
Benzinga · 3h ago
uniQure GAAP EPS of -$6.47 misses by $0.21, revenue of $15.84M beats by $1.04M
Seeking Alpha · 6h ago
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress
Barchart · 12h ago
Weekly Report: what happened at QURE last week (0219-0223)?
Weekly Report · 2d ago
Possible Signal As uniQure Insiders Sell US$1.8m In Stock
UniQure N.V. Insiders sold US$1.8m worth of stock in the past 12 months. The biggest insider sale was by the CEO of uniqure, Matthew Kapusta, for US$493k. In the last year, there were no insider purchases of unaQure shares. The company has a low insider ownership of 1.5% of the company. It's important to keep in mind uniQures insider transactions are not a cause for concern.
Simply Wall St · 02/21 12:39
Weekly Report: what happened at QURE last week (0212-0216)?
Weekly Report · 02/19 09:11
Weekly Report: what happened at QURE last week (0205-0209)?
Weekly Report · 02/12 09:11
Weekly Report: what happened at QURE last week (0129-0202)?
Weekly Report · 02/05 09:11
uniQure: The Valuation Got More Attractive
UniQure is valued at close to $33/share. In 2023, uniQure achieved approval for its HEMGENIX treatment in US & EU and sale of its royalty interests in it. The company has been undervalued by the market since its last valuation in May of 2023. Since then, the company has achieved some major milestones.
Seeking Alpha · 02/01 19:25
Weekly Report: what happened at QURE last week (0122-0126)?
Weekly Report · 01/29 09:11
Uniqure: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/25 16:10
Buy Rating Affirmed on uniQure’s Advancing Gene Therapy Pipeline and Anticipated Regulatory Progress
TipRanks · 01/22 18:45
Weekly Report: what happened at QURE last week (0115-0119)?
Weekly Report · 01/22 09:11
Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
UniQure N.V. Shares have lost 29% in the last month. The company's price-to-sales ratio of 2.5x is lower than its industry peers. UniQure grew revenue by 82% last year and is expected to grow by 11% over the next three years. However, the company's P/S ratio may be sending out the wrong signals to shareholders.
Simply Wall St · 01/17 10:50
RBC Capital Reiterates Outperform on uniQure, Maintains $28 Price Target
Benzinga · 01/16 14:12
RBC Capital Reaffirms Their Buy Rating on uniQure (QURE)
TipRanks · 01/16 01:47
Weekly Report: what happened at QURE last week (0108-0112)?
Weekly Report · 01/15 09:11
More
Webull provides a variety of real-time QURE stock news. You can receive the latest news about Uniqure through multiple platforms. This information may help you make smarter investment decisions.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.